Tristel focuses on infection control products for acute NHS and private sector hospitals, as well as primary care trusts, community hospitals and private practices. Tristel also provides products for legionella control in water systems and contamination control in the food growing, food processing and pharmaceutical industries. Tristel is an aldehyde-free sterilant that can meet all the chemical decontamination needs of a hospital, safely and economically. As a result, Tristel has now become the most widely-used sterilant in UK hospitals. A patented chlorine dioxide chemistry used to sterilise medical, dental and veterinary instruments is the cornerstone of Tristel Solutions which was formed in Cambridgeshire, England in 1998. Tristel products are emerging as the leading replacements for aldehyde-based disinfectants, which have been the universal choice of disinfectant in all countries worldwide for the past two decades. However, because of health and environmental concerns, aldehyde-based disinfectants are being withdrawn in many countries. In England, Scotland and Wales, Tristel Solutions markets its products directly to National Health Service and private sector hospitals, GP practices, dental and veterinary establishments. The Tristel sterilants are manufactured in an ISO 9001:2000 accredited plant in Snailwell, England.
Show more
Snailwell, GB
Size (employees)
111 (est)+13%
Tristel was founded in 1998 and is headquartered in Snailwell, GB
Report incorrect company information

Tristel Office Locations

Tristel has an office in Snailwell
Snailwell, GB (HQ)
Fordham Rd
Show all (1)
Report incorrect company information

Tristel Financials and Metrics

Tristel Financials

Tristel's revenue was reported to be £15.21 m in FY, 2017

Revenue (FY, 2017)

15.2 m

Gross profit (FY, 2017)

10.8 m

Gross profit margin (FY, 2017), %


Net income (FY, 2017)

2.9 m

EBITDA (FY, 2017)

3.4 m

EBIT (FY, 2017)

2.9 m

Market capitalization (31-Oct-2017)

116.7 m

Closing share price (31-Oct-2017)


Cash (30-Jun-2017)

1.6 m
Tristel's current market capitalization is £116.7 m.
GBPFY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017


4 m4.9 m5.9 m8 m9.3 m10.5 m10 m12.7 m14.7 m14.9 m15.2 m

Revenue growth, %


Cost of goods sold

1.5 m1.6 m2.1 m2.9 m3.5 m3.6 m3.7 m4.3 m4.8 m4.3 m4.4 m

Gross profit

2.5 m3.4 m3.8 m5.1 m5.8 m6.8 m6.3 m8.4 m9.9 m10.6 m10.8 m
GBPFY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

49.6 k564.9 k210.2 k480.9 k98.8 k157.4 k(1.5 m)165.9 k1.3 m2.3 m2.9 m

Cash From Operating Activities

338.9 k985.1 k715.5 k(223.2 k)3.4 m1.6 m377.8 k487.6 k2.8 m4.4 m

Dividends Paid

800 k2.8 m4.1 m

Cash From Financing Activities

99.8 k1.3 k(47.2 k)(1.2 m)(1.2 m)(91.2 k)(60.2 k)(65.4 k)(860 k)(2.8 m)
GBPY, 2017


144.9 k

Financial Leverage

12.6 x
Show all financial metrics
Report incorrect company information